Novartis India (NOVARTIND) Share Price Falls 6.19% Today; What the Decline Shows
- September 15, 2026
- Posted by: Harsh Piplani
- Category: News
Novartis India Share Price fell to Rs 2,245 on 15 September 2026, down 6.19% or Rs 148.15 from the previous close of Rs 2,393.15. The move left the company with a market capitalisation of Rs 5,908.88 crore. The stock opened at Rs 2,336.25 and weakened further toward an intraday low of Rs 2,209.60.
The supplied data confirms a sharp single-day decline. It also shows the stock remained below its opening level for much of the session range, even though it touched an intraday high of Rs 2,373.05. Turnover stood at Rs 0.90 crore at the time of the update. The dataset establishes the price move, but it does not establish any company-specific catalyst for why the stock is falling today.
That makes the numbers themselves the main guide. The decline is drawing attention because the stock still sits well above its longer-term moving averages, while valuation and profitability metrics place it in a notable position within the Trading industry. For investors, the key questions now are whether the stock stabilises after this move and how its valuation compares with sector benchmarks and peers.
Novartis India (NOVARTIND) Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 2,245 |
| Previous Close | Rs 2,393.15 |
| Today's Move | -Rs 148.15 (-6.19%) |
| Open | Rs 2,336.25 |
| High | Rs 2,373.05 |
| Low | Rs 2,209.6 |
| Turnover | Rs 0.9 crore |
| Market Capitalisation | Rs 5,908.88 crore |
| Market Cap Category | Mid Cap |
Novartis India Share Price Today reflects a clear intraday decline. The stock moved from a previous close of Rs 2,393.15 to Rs 2,245, a loss of Rs 148.15 or 6.19%. It opened at Rs 2,336.25, reached a day high of Rs 2,373.05 and later slipped to Rs 2,209.60, showing that weakness emerged early and remained visible through the session.
For a Mid Cap stock, that kind of move often becomes a market talking point quickly, especially when the current price stays below both the previous close and the opening level. The intraday range between Rs 2,209.60 and Rs 2,373.05 also suggests active repricing rather than a small drift lower. Turnover of Rs 0.90 crore points to measurable trading interest around the fall.
Technical context also stands out. The supplied RSI is 85.23, while the 50-day moving average is Rs 1,615.95 and the 200-day moving average is Rs 1,260.63. Even after today’s decline, the stock remains far above both long-term averages, which means the day’s weakness should be viewed alongside a still-elevated longer-term price base.
Novartis India (NOVARTIND) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 5,908.88 crore |
| P/E Ratio | 60.44x |
| P/B Ratio | 6.95x |
| ROE | 13.19% |
| ROCE | 17.15% |
| EPS | Rs 39.6 |
| Book Value Per Share | Rs 344.28 |
| Dividend Yield | 0% |
Novartis India has a market capitalisation of Rs 5,908.88 crore, placing it in the Mid Cap bracket. The stock trades at a P/E ratio of 60.44 and a P/B ratio of 6.95, indicating that the market values its earnings and book value at a premium to many companies in the same industry.
On profitability, the company reports ROE of 13.19% and ROCE of 17.15%. Those are healthy double-digit return ratios and help explain why the stock may continue to draw attention despite today’s decline. EPS stands at Rs 39.6, while book value per share is Rs 344.28. The supplied dividend yield is 0, so the current dataset does not indicate a cash yield at the prevailing market price.
Taken together, the picture is balanced rather than one-sided. Profitability looks stronger than a typical industry participant, but valuation multiples remain elevated enough to deserve close tracking after a sharp down day.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Trading |
| Industry | Trading |
| Benchmark Scope | same industry |
| Company P/E Ratio | 60.44x |
| Benchmark Median P/E | 24.19x |
| Benchmark Average P/E | 113.26x |
| Benchmark P/E Range | 0.12x to 8,715.25x |
| Company P/B Ratio | 6.95x |
| Benchmark Median P/B | 1.39x |
| Benchmark Average P/B | 4.85x |
| Company ROE | 13.19% |
| Benchmark Median ROE | 4.03% |
| Benchmark Average ROE | 5.08% |
| Company ROCE | 17.15% |
| Benchmark Median ROCE | 5.88% |
| Benchmark Average ROCE | 7.57% |
| Company Market Capitalisation | Rs 5,908.88 crore |
| Benchmark Median Market Cap | Rs 51.56 crore |
| Benchmark Average Market Cap | Rs 1,626.62 crore |
The sector snapshot places the company in the Trading sector and Trading industry, with the benchmark universe covering 479 companies. In that context, the company’s P/E of 60.44 is well above the industry median of 24.19, though below the industry average of 113.26. Because the benchmark P/E range runs from 0.12 to 8,715.25 across 343 companies, the average is skewed by outliers, making the median especially useful for perspective.
On P/B, the company’s 6.95 is above the industry median of 1.39 and above the average of 4.85. That again points to a premium valuation. At the same time, profitability is stronger than the benchmark centre: ROE of 13.19% is above the median of 4.03% and average of 5.08%, while ROCE of 17.15% is above the median of 5.88% and average of 7.57%.
Size also matters here. Novartis India’s market capitalisation of Rs 5,908.88 crore is well above the industry median of Rs 51.56 crore and the average of Rs 1,626.62 crore. So the stock is larger and more profitable than a typical industry company, but it is also priced at richer multiples than the median benchmark participant.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Adani Enterprises | ADANIENT | 4,13,846.54 | 55.59 | 4.39 | 15.07 | 13.3 |
| Aegis Logistics | AEGISLOG | 47,493.81 | 37.96 | 7.2 | 20.71 | 19.76 |
| ADITYA INFOTECH | CPPLUS | 45,310.84 | 94.94 | 22.48 | 25.68 | 29.48 |
| Premier Energies | PREMIERENE | 44,239.84 | 26.57 | 9.3 | 42.6 | 33.72 |
| Redington | REDINGTON | 30,774.55 | 18.09 | 2.9 | 13.6 | 18.96 |
Peer data adds useful perspective. Versus Adani Enterprises, Novartis India trades at a slightly higher P/E of 60.44 against 55.59, with lower ROE but a higher ROCE. Compared with Aegis Logistics, it carries a higher P/E, a slightly lower P/B, and weaker profitability on both ROE and ROCE.
Against ADITYA INFOTECH, Novartis India looks cheaper on both P/E and P/B, but it also posts lower returns. Compared with Premier Energies and Redington, the picture stays mixed. Premier Energies has a much lower P/E and markedly stronger returns, while Redington trades at only 18.09 times earnings with ROE of 13.6% and ROCE of 18.96%, both around or above Novartis India’s current levels.
Market-cap-wise, Novartis India at Rs 5,908.88 crore is much smaller than all five named peers, whose capitalisations range from Rs 30,774.55 crore to Rs 4,13,846.54 crore. That leaves the stock as a smaller listed player with decent profitability, but not an obviously inexpensive one when compared with several larger peers.
Why Investors Are Watching Novartis India
- A 6.19% single-day decline pushed the stock to Rs 2,245 from Rs 2,393.15.
- The stock moved between Rs 2,209.60 and Rs 2,373.05, showing a wide intraday price band.
- P/E of 60.44 and P/B of 6.95 place valuation above industry medians.
- ROE of 13.19% and ROCE of 17.15% are stronger than industry median and average levels.
- The stock remains far above its 50-DMA of Rs 1,615.95 and 200-DMA of Rs 1,260.63 even after today’s fall.
About Novartis India
Novartis India is classified in the supplied dataset under the Trading sector and Trading industry. From a market perspective, that places it inside a broad comparison set where valuation multiples and profitability vary widely, making relative analysis important.
With a market capitalisation of Rs 5,908.88 crore, the company sits above the industry’s median size but below major listed peers such as Adani Enterprises, Aegis Logistics, Premier Energies and Redington. That middle position helps explain why a sharp move in the stock can attract broader market attention.
Track Novartis India Share Price on Univest
UseNovartis India (NOVARTIND) live share-price page,Univest top decliners screener,Univest market blogsto review live stock data, top decliners and related market analysis.
Investors tracking Novartis India Share Price can use Univest to follow live price moves, valuation ratios, peer comparison and market-cap context in one place. That can help connect daily price action with broader fundamental and industry data.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
Why is Novartis India Share Price falling today?
Ans. The supplied data confirms that the stock fell 6.19% to Rs 2,245 from the previous close of Rs 2,393.15. However, the dataset does not establish a company-specific catalyst for today’s decline.
What is Novartis India Share Price Today?
Ans. Novartis India Share Price Today is Rs 2,245 at the time of the update. That is down Rs 148.15 or 6.19% from the previous close of Rs 2,393.15. The intraday range extended from Rs 2,209.6 to Rs 2,373.05.
What does today's price action show for Novartis India?
Ans. The stock opened at Rs 2,336.25, touched a high of Rs 2,373.05 and a low of Rs 2,209.60. Trading below the open and previous close points to clear intraday weakness.
What is the market capitalisation of Novartis India?
Ans. Novartis India has a market capitalisation of Rs 5,908.88 crore. The supplied dataset classifies it as a Mid Cap company. The company operates in the Trading sector. Its P/E ratio is 60.44x.
Is Novartis India expensive compared with its industry?
Ans. On the supplied numbers, the company trades at 60.44 times earnings versus the same-industry median P/E of 24.19. Its P/B ratio of 6.95 is also above the industry median of 1.39, suggesting a premium valuation.
How does Novartis India compare with major peers?
Ans. Its P/E of 60.44 is above Aegis Logistics and Redington, close to Adani Enterprises, and below ADITYA INFOTECH. Its profitability is decent, but several larger peers show stronger return ratios.
What should investors monitor next?
Ans. Investors can monitor whether the stock stabilises after falling to Rs 2,245, how valuation compares with peers, and whether profitability metrics such as ROE of 13.19% and ROCE of 17.15% continue to support market interest.
